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Abstract
Background: Approximately one out of every ten cases of epithelial ovarian cancer (EOC) is inherited. The majority of
inherited cases of EOC result from mutations in the breast cancer associated gene 1 (BRCA1). In addition to mutation of
BRCA1, mutation of the p53 gene is often found in patients with inherited breast and ovarian cancer syndrome.
Methodology/Principal Findings: We investigated the role of loss of function of BRCA1 and p53 in ovarian cancer
development using mouse models with conditionally expressed alleles of Brca1 and/or p53. Our results show that ovary-
specific Cre-recombinase-mediated conditional inactivation of both Brca1
LoxP/LoxP and p53
LoxP/LoxP resulted in ovarian or
reproductive tract tumor formation in 54% of mice, whereas conditional inactivation of either allele alone infrequently
resulted in tumors (#5% of mice). In mice with conditionally inactivated Brca1
LoxP/LoxP and p53
LoxP/LoxP, ovarian tumors arose
after long latency with the majority exhibiting histological features consistent with high grade leiomyosarcomas lacking
expression of epithelial, follicular or lymphocyte markers. In addition, tumors with conditional inactivation of both
Brca1
LoxP/LoxP and p53
LoxP/LoxP exhibited greater genomic instability compared to an ovarian tumor with inactivation of only
p53
LoxP/LoxP.
Conclusions/Significance: Although conditional inactivation of both Brca1 and p53 results in ovarian tumorigenesis, our
results suggest that additional genetic alterations or alternative methods for targeting epithelial cells of the ovary or
fallopian tube for conditional inactivation of Brca1 and p53 are required for the development of a mouse model of Brca1-
associated inherited EOC.
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Introduction
Approximately 10% of cases of epithelial ovarian cancer (EOC)
are associated with a clear hereditary predisposition to disease; the
vast majority of cases resulting from inherited alterations in the
breast cancer-associated tumor suppressor genes 1 or 2 (BRCA1 or
BRCA2) (reviewed in: [1,2,3]). BRCA1 and BRCA2 were originally
identified based on genetic linkage to families with an increased
risk of breast and ovarian cancer. The proteins encoded by these
genes control normal cellular growth by their involvement in DNA
damage repair, maintenance of genomic integrity, chromatin
remodeling and transcription regulation [4,5]. Linkage to the
BRCA1 gene exists in ,80% of families with inherited risk of
breast and ovarian cancer [1,2,3]. Although mutations of the
BRCA1 gene are not frequently detected in sporadic cases of EOC,
recent studies have suggested that other mechanisms of inactiva-
tion of this tumor suppressor gene, such as promoter methylation
and mutations in non-coding regions that effect functional protein
expression, may exist in sporadic tumors [6,7,8,9,10]. In addition
to alterations in BRCA1 and BRCA2, mutation of the p53 gene is
reported in 70–90% of patients with familial breast and ovarian
cancer syndrome [11,12,13,14]. Interestingly, p53 mutations are
identified more frequently in BRCA1-associated and sporadic
serous ovarian carcinomas than in sporadic ovarian cancers of
other histologic subtypes [11,12,13,14]. A role for p53 in BRCA1-
associated inherited breast and ovarian cancer is further supported
by the cooperation of p53 with BRCA1 in the development of
mammary tumor development in genetically engineered mouse
(GEM) models [15,16].
Despite recent advances in the development of GEM models of
EOC [17,18,19,20,21] and the existence of mouse models of
Brca1-associated inherited breast cancer [15,16], analogous mouse
models that develop Brca1-associated inherited invasive EOC have
been more difficult to develop. The delay in developing such a
model owes largely to controversy over the identity of the cell type
of origin of BRCA1-associated inherited invasive EOC and the
resultant difficulty in targeting molecular alterations to the correct
cell type. Because homozygous deletion of Brca1 leads to early
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have employed strains of mice with conditional inactivation of
Brca1. Two previous studies [22,23] investigated the effects of
ovary-specific conditional inactivation of Brca1 using distinct
genetically engineered strains of mice harboring LoxP-flanked
alleles of Brca1 [16,24]. In these studies, ovary-specific Cre-
recombinase expression was achieved by genetic means [22] or by
direct administration of adenovirus encoded Cre-recombinase [23].
In both cases, ovary-specific conditional inactivation of Brca1 led
to the development of pre-neoplastic [23] or benign [22] epithelial
lesions in the ovary, but in neither case were invasive ovarian
cancers observed. A separate study, using an ex vivo retroviral
transduction strategy for conditional inactivation of LoxP-flanked
Brca1 and p53 alleles in ovarian explants, showed that inactivation
of both Brca1 and p53 in conjunction with expression of Myc led to
transformation of ovarian cells and that these cells were
tumorigenic in recipient mice [25]. In the present study, we
sought to extend these previous observations by testing whether
conditional inactivation of Brca1 and p53 in the ovarian surface
epithelium in situ is sufficient to establish an autochthonous mouse
model of BRCA1-associated invasive EOC. To this end, we used
previously established strains of genetically engineered mice
harboring LoxP-flanked Brca1 [16] in conjunction with mice
harboring LoxP-flanked p53 [26] or a missense gain-of-function
mutant allele of p53 [27] that is analogous to the R175H hotspot
mutation frequently identified in human cancers [28,29,30].
Results
Intrabursal Administration of Adenovirus Results in
Efficient Infection of Ovarian Surface Epithelial Cells
Because Brca1
2/2 (knockout) mice are embryonic lethal and
p53
2/2 mice develop and succumb from tumors (e.g., lymphoma,
sarcoma, etc.) at young ages, the present study utilized genetically
engineered mouse strains that express LoxP recombination sites
within the Brca1 and p53 alleles, thus allowing conditional
inactivation of each allele upon exposure to Cre-recombinase
[31]. Since there are no existing mouse models that exhibit
ovarian surface epithelium (OSE)-restricted expression of Cre-
recombinase, we chose a viral approach for conditional Cre-
mediated inactivation of LoxP-flanked alleles by intrabursal
administration of Adenovirus-Cre. To demonstrate our capability
to successfully perform intrabursal injections that result in OSE-
restricted viral infection, we performed pilot experiments in which
8 week-old female C57Bl/6 mice received intrabursal injections of
Ad5-CMV-ntLacZ as previously described [18,19,21,23]. To test
the extent and localization of viral infection, eight week-old female
C57Bl/6 mice were given intrabursal injections of 5610
7 p.f.u. of
Ad5-CMV-ntLacZ and euthanized one week post-surgery.
Ovaries were dissected, snap frozen, sectioned and stained for b-
galactosidase expression. Single intrabursal injection of Ad5-
CMV-ntLacZ resulted in high efficiency, tissue restricted infection
of the OSE with little or no infection of the underlying ovarian
stromal tissue as shown by the b-galactosidase staining of thin
sections of ovary (Figure 1A, panels a and b). Although staining
was predominantly confined to the OSE, occasional b-galactosi-
dase positive cells were observed in the fallopian tube (1A, panel c).
No evidence of b-galactosidase staining was detected in the uterus
or other organs indicating that viral infection had not spread
beyond the site of injection (data not shown).
Cre-LoxP-Mediated Conditional Inactivation of Brca1
To confirm infection with Ad5-CMV-Cre and tissue-restricted
Cre-mediated excision of LoxP-flanked sequences, Brca1
LoxP/LoxP
mice received intrabursal injection of Ad5-CMV-Cre and were
euthanized one week post-surgery and the ovaries, uterus and liver
were excised. Because the OSE is a comparatively small
component of the total ovary, detection of Cre-mediated excision
of LoxP flanked sequences in the ovaries of Brca1
LoxP/LoxP mice
would likely be obscured if genomic DNA from the entire ovary
was used for PCR amplification and detection of excision. To
circumvent this issue, we prepared a tissue lysate enriched for
digested OSE by limiting the initial digestion time of ovary
specimens to 30 min. The remainder of the undigested ovary was
then digested overnight. Genomic DNA was isolated from each
tissue and PCR amplified using both the forward and reverse
primers for Brca1 introns 4 and 13. Cre-mediated excision of
LoxP-flanked sequences of Brca1
LoxP/LoxP was detected by ampli-
fication with Brca1-int4-Fwd and Brca1-int13-Rev primers. As
expected, PCR amplification resulted in detection of LoxP flanked
sequences in all tissues of the Brca1
LoxP/LoxP mice (Figure 1B).
Importantly, the excised Brca1
D5-13 product was detected only after
short (30 min) digestion of the ovary and not in the liver, uterus or
the remainder of the ovary specimens that were digested overnight
(Figure 1C). These results confirm successful infection of the ovary
by Ad5-CMV-Cre and Cre-mediated excision of LoxP-flanked
Brca1 sequences. Moreover, the absence of the excised Brca1
D5-13
product in the ovary specimens digested overnight (Figure 1C)
suggests that the Ad5-CMV-Cre infection is limited to the outer
part of the ovary (the OSE) without substantial penetration of the
ovarian cortex or infection of uterus or other peritoneal organs.
Based on the successful demonstration of efficient, tissue-
restricted infection with the Ad5-CMV-ntLacZ and Ad5-CMV-
Cre viruses, we commenced with intrabursal Ad5-CMV-
Cre injection of the following groups of mice: 1) Brca1
LoxP/LoxP,
2) p53
LoxP/LoxP,3 )Brca1
LoxP/LoxP;p53
LoxP/LoxP,4 )Brca1
LoxP/LoxP;
p53
+/515A and 5) Brca1
LoxP/LoxP;p53
LoxP/515A. The total number of
mice receiving bilateral or unilateral injection of Ad5-CMV-Cre
or unilateral injection of PBS (control) for each group is
summarized in Table 1.
Conditional Loss of Brca1 or p53 Alone Infrequently
Results in Ovarian Tumor Formation
A total of 51 Brca1
LoxP/LoxP mice were evaluated (see Table 1 and
Figure 2A), including 40 mice that received bilateral and 5 mice
that received unilateral injection of Ad5-CMV-Cre as well as 6
unilateral PBS injected controls. The reproductive tracts and
pathologically altered organs were isolated from all of these mice
and subjected to histopathological evaluation (by L.H.E.). Of these
51 mice, 9/40 mice (23%) that received bilateral Ad5-CMV-Cre
injection and 1/6 (17%) mice that received unilateral PBS
injection developed tumors (Table 1) after long latency (i.e.,
average=491626 days after Ad5-CMV-Cre injection). No
ovarian or reproductive tract tumors were detected (Figure 2A),
and 8/9 tumors arising in bilaterally injected mice and the single
tumor arising in a PBS injected mouse were extra-peritoneal.
Because the tumors were located at sites distant from the site of
Ad5-CMV-Cre injection, we considered the possibility that
intrabursal injection of virus was leaky resulting in local or
systemic infection beyond the original site of injection. To test this
experimentally, genomic DNA was isolated from each of these
tumors and subjected to PCR amplification of LoxP-flanked Brca1
sequences in introns 4 and 13 and the excised Brca1
D5-13 product.
Importantly, the Brca1
D5-13 excision product was not detected in
any of the tumors identified in the Brca1
LoxP/LoxP mice (Table 1 and
data not shown). These results suggest that the tumors observed
were sporadic and unrelated to the Cre-mediated excision of
Brca1
LoxP/LoxP resulting from local or systemic viral infection. The
Brca1 and p53 Ovarian Tumors
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[22,23,25] demonstrating that inactivation of Brca1 alone is
insufficient for malignant transformation in the mouse ovary.
Among the p53
LoxP/LoxP mice evaluated in this study (n=53), 41
received bilateral and 6 received unilateral injections of Ad5-
CMV-Cre and 6 received unilateral injection with PBS (Table 1).
None of the control PBS injected mice developed tumors, but a
low frequency of tumor formation (3/53 mice) was observed in
Ad5-CMV-Cre injected mice (Table 1 and Figure 2A). Specifi-
cally, one mouse developed a large palpable ovarian mass 132
days after bilateral Ad5-CMV-Cre injection, one mouse developed
a small mass at the end of one of the uterine horns 373 days after
unilateral injection of Ad5-CMV-Cre, and one control mouse
developed a palpable subcutaneous mass located near the scapulae
353 days after PBS injection. Analysis of the genomic DNA
isolated from the ovarian and uterine tumors resulted in
amplification of the excised p53
D2-10 product (Figure 2B and data
not shown), whereas no excision product was amplified from the
DNA isolated from the subcutaneous scapular tumor. These
results suggest that conditional inactivation of p53 alone rarely
results in ovarian tumor development (1/47 cases, 2%). This
finding is again consistent with a previous study [19] reporting low
frequency of ovarian tumor development (2/31 cases, 6%) after
intrabursal Adenovirus-cre mediated conditional inactivation of
p53.
Conditional Loss of Both Brca1 and p53 Cooperates to
Induce Ovarian Tumors
To determine whether inactivation of both Brca1 and p53 in the
OSE can cooperate to induce ovarian tumorigenesis, we evaluated
ovarian tumor formation in Brca1
LoxP/LoxP;p53
LoxP/LoxP, Brca1
LoxP/LoxP;
p53
+/515A and Brca1
LoxP/LoxP;p53
LoxP/515A mice following intrabursal
Figure 1. Intrabursal injection of Adenovirus results in ovarian surface epithelial cell-restricted infection. A) Histochemical detection of
b-galactosidase expression in tissue sections of ovaries of a wild type mouse that received intrabursal injection of Ad5-CMV-LacZ show staining of the
ovarian surface epithelium and absence of staining of the underlying ovarian cortex (panels a and b). Occasional b-galactosidase positive cells were
also observed in fallopian tube (panel c) while no staining was observed in a control mouse injected with PBS (panel d). Scale bars in each image
represent 100 mm. B) PCR amplification of LoxP containing sites in introns 4 (top) and 13 (bottom) of Brca1 in Brca1
LoxP/LoxP, Brca1
wt/wt, Brca1
wt/D5-13
and Brca1
WT/LoxP mice. Genomic DNA was isolated after digestion with proteinase K from the following tissues: liv–liver, t–tail, ut–uterus, ov 309–ovary
after 30 minute digestion and ov 12 h–ovary after 12 hours of digestion. The sizes of the LoxP flanked and wild type (wt) intron 4 and 13 PCR
products are indicated. C) PCR amplification of 594 nt excised Brca1
D5-13 allele was detected only in the ovary exposed to digestion for 30 minutes
and in the genomic DNA isolated from a Brca1
wt/D5-13 mouse.
doi:10.1371/journal.pone.0008404.g001
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515A
mice used in the current study constitutively expressed the arginine to
histidine substitution at amino acid 172 of p53. As previouslyreported
[27], mice harboring the homozygous constitutively expressed
mutant p53
515A/515A allele developed tumors with an incidence,
latency and spectrum (e.g., lymphomas and sarcomas) similar to that
of homozygous p53 knockout mice [32,33]. Ovarian tumors were not
detected in any of the Brca1
LoxP/LoxP;p53
+/515A and Brca1
LoxP/LoxP;
p53
LoxP/515A mice at the time of euthanasia; therefore, these two
groups were not informative for this study.
A total of 47 Brca1
LoxP/LoxP;p53
LoxP/LoxP mice were evaluated.
Among these, 35 received bilateral Ad5-CMV-Cre injection, 6
received unilateral Ad5-CMV-Cre injection and 6 control mice
were injected with PBS (Table 1). Tumors were detected in 20/35
(57%) mice with bilateral and 4/6 (66%) mice with unilateral
injection of Ad5-CMV-Cre (Table 1 and Figure 2A) after long
latency (409681 days after Ad5-CMV-Cre injection). Pair-wise
log-rank tests showed that Brca1
LoxP/LoxP;p53
LoxP/LoxP mice had
significantly shorter average survival after conditional inactivation
of LoxP flanked alleles than Brca1
LoxP/LoxP or p53
LoxP/LoxP mice
(p,0.000001 and p,0.05 respectively). Among the 24 total
tumors, we were able to demonstrate Cre-mediated excision of
LoxP flanked sequences of both Brca1
LoxP/LoxP and p53
LoxP/LoxP in
23 cases (Table 2, Figure 2B and data not shown). The majority
(22/23) of the tumors detected in Brca1
LoxP/LoxP;p53
LoxP/LoxP mice
were associated with the ovaries and reproductive tract, and all
exhibited Cre-mediated excision of LoxP flanked sequences
(Table 2). Among these, there were 7 leiomyosarcomas of the
ovary, 4 leiomyosarcomas of the ovary and uterus, 8 ovarian
sarcomas, one malignant teratoma, one sclerosing stromal tumor
of the uterus and one uterine adenocarcinoma. The only case in
which the Brca1
D5-13 and p53
D2-10 excision products were not
detected was a peritoneal sarcoma that was not associated with the
reproductive tract. Thus, conditional loss of both Brca1 and p53 in
the ovary leads to a high frequency of ovarian and reproductive
tract tumor formation.
Histopathological Features of Tumors Arising in Mice
with Conditionally Inactivated Brca1 and/or p53
With the exception of one unclassifiable necrotic peritoneal
mass, all of the tumors identified in Brca1
LoxP/LoxP mice were
classified as carcinomas. Among these was one vaginal squamous
carcinoma, two subcutaneous adenocarcinomas located near the
scapulae and five lung adenocarcinomas (not shown). PCR
amplification of the excised Brca1
D5-13 product was not detected
in any of these cases leading to the conclusion that these
carcinomas were sporadic in nature. The relatively high frequency
of sporadic tumor occurrence in this strain of mice remains
unexplained.
In contrast to previous studies [22,23], the ovaries of Ad5-
CMV-Cre injected Brca1
LoxP/LoxP mice were histologically unre-
markable and did not exhibit noteworthy morphological or
histological changes of the OSE indicative of pre-neoplastic or
neoplastic growth. Brca1
LoxP/LoxP mice that received bilateral
intrabursal Ad5-CMV-Cre injections were observed for an
average of 475 days (6102 days) prior to euthanasia suggesting
that conditional inactivation of Brca1 alone is insufficient to cause
ovarian tumors even after long latency.
Histopathological evaluation of the single ovarian mass
detected in a p53
LoxP/LoxP mouse that received bilateral Ad-
Table 1. Summary of tumor incidence following intrabursal injection of Ad5-CMV-Cre recombinase.
Genotype
Total number of mice
evaluated
Mice with any type of
tumor (%)
Tumors with Cre-mediated conditional
inactivation (%)*
Brca1
LoxP/LoxP
Bilateral Ad-Cre 40 9 (23) 0
Unilateral Ad-Cre 5 0 0
PBS 6 1 (17) 0
p53
LoxP/LoxP
Bilateral Ad-Cre 41 2 (5) 2 (5)
Unilateral Ad-Cre 6 1 (17) 0
PBS 6 0 0
Brca1
LoxP/LoxP;p53
LoxP/LoxP
Bilateral Ad-Cre 35 20 (57) 19 (54)
Unilateral Ad-Cre 6 4 (66) 4 (66)
PBS 6 0 0
Brca1
LoxP/LoxP;p53
515C/WT
Bilateral Ad-Cre 44 7 (16) 0
Unilateral Ad-Cre 6 2 (33) 0
PBS 6 0 0
Brca1
LoxP/LoxP;p53
515C/LoxP
Bilateral Ad-Cre 15
# 3 (20) 2 (13)
Unilateral Ad-Cre 3
# 00
PBS 2
# 00
*Confirmed by PCR amplification of excised product.
#Accrual terminated based on results from prior groups.
doi:10.1371/journal.pone.0008404.t001
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leiomyosarcoma (Figure 3A). The tumor was composed of
spindle cells with marked cytologic atypia and numerous mitotic
figures, including abnormal mitotic figures. The only other
tumor detected in this group was a small uterine mass classified
as a uterine leiomyosarcoma. In Brca1
LoxP/LoxP;p53
LoxP/LoxP mice
that received bilateral Ad5-CMV-Cre injection, 23/41 (56%)
mice developed confirmed Brca1
D5-13;p53
D2-10–associated tu-
mors, most of which were ovarian. Among the ovarian tumors,
the majority were categorized as soft tissue tumors including
ovarian leiomyosarcomas (n=12) and high grade sarcomas that
could not be further classified (n=4). These leiomyosarcomas
exhibited spindle cells with marked atypia and the high grade
sarcomas demonstrated pleiomorphic atypia without other
specific morphologic features (Figure 3A). The ovarian tumors
identified were highly proliferative as evidenced by nearly
uniform PCNA staining (Figure 3A, panels c, g, and k) and,
consistent with Cre-mediated inactivation of p53
LoxP/LoxP, lacked
expression of p53 (Figure 3A, panels d, h, and l). The ovarian
tumors also lacked histopathological features or immunohisto-
chemical staining of granulosa cell (a-inhibin), epithelial (CK8
and CK 19), lymphoid (CD3 and CD45R) or a-smooth muscle
actin (a-SMA) differentiation (Figure 3B and data not shown).
Thus, while conditional inactivation of both Brca1 and p53
resulted in a high frequency of ovarian tumor development, no
ovarian carcinomas were detected.
Brca1 and p53 Tumors Exhibit Genomic Instability
Genomic DNA isolated from the single p53
D2-10 ovarian
leiomyosarcoma and two cases of Brca1
D5-13;p53
D2-10 ovarian
leiomyosarcomas was subjected to array based comparative
genomic hybridization (aCGH) analysis. The p53
D2-10 ovarian
leiomyosarcoma (case number 627) exhibited gains and/or losses
of entire chromosomes analogous with aneuploidy and occasional
isolated regions of DNA copy number alterations (Figure 4A). By
comparison, the Brca1
D5-13;p53
D2-10 ovarian leiomyosarcomas
(case numbers 307 and 399) exhibited a much more complex
array of genetic copy number alterations including entire
chromosomal gains and losses as well as distinct regions of DNA
gains and losses within the same chromosome (Figure 4A); results
suggestive of a high degree of chromosomal damage. Karyotypic
analysis of a tumor cell line established from Brca1
D5-13;p53
D2-10
ovarian leiomyosarcoma case number 399 supported this
observation. A total of 26 metaphase spreads were analyzed, 22
of which were karyotyped (Figure 4B). The number of chromo-
somes per individual metaphase ranged from 65 to 143, with no
clear modal number. However, 18 metaphases were near-
tetraploid, with chromosome counts ranging from 65–87. Seven
metaphases had counts ranging from 97–143. The remaining
metaphases showed a high level of chromosomal damage with
many fragments, double minutes and a tri-radial rearrangement.
Four of the metaphases had 1–3 chromosome or chromatid
Figure 2. Incidence and latency of reproductive tract tumors in
female mice with conditional inactivation of LoxP flanked
alleles of Brca1 and/or p53. A) Fraction of tumor free mice after
intrabursal injection of Adenovirus-Cre recombinase. B) Genotyping
analysis of DNA isolated from Brca1
D5-13;p53
D2-10 and p53
D2-10 ovarian
tumors. Both the Lox P flanked and excised Brca1 and p53 alleles were
amplified from Brca1
D5-13;p53
D2-10 tumors (cases 307, 350, 352 355, 397,
399, 411 and 412) and the Lox P flanked and excised p53 allele was
amplified from the single p53
D2-10 ovarian tumor (case 627). In each
panel the left lane contains a DNA ladder and the sizes of the amplified
products (nt) are indicated at the right.
doi:10.1371/journal.pone.0008404.g002
Table 2. Summary of tumors associated with Cre-mediated inactivation of Brca1 and/or p53.
Genotype
Total number of
mice evaluated
Tumors with Cre-mediated
conditional gene inactivation
Reproductive tract tumors with Cre-mediated
conditional gene inactivation
Brca1
D5-13 45 0 0
p53
D2-10 47 2 (4%) 2 (4%)
Brca1
D5-13;p53
D2-10 41 23 (56%) 22 (54%)
doi:10.1371/journal.pone.0008404.t002
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fragments. Thus, the cytogenetic analysis of this tumor cell line
revealed considerable genomic instability. Due to the absence of
Brca1
D5-13 tumors were unable to assess chromosomal stability in
mice with conditional inactivation of Brca1 alone; however, these
results support the hypothesis that loss of Brca1 function leads to a
high degree of genetic instability thus contributing to ovarian
tumorigenesis.
Figure 3. Histopathological characterization of ovarian tumors arising in Brca1
D5-13;p53
D2-10 and p53
D2-10 mice after intrabursal
administration of Ad5-CMV-Cre. A) Low (panels a, e, and i) and high (panels b, f, and j) magnification of H&E stained sections of tumors isolated
from two Brca1
D5-13;p53
D2-10 mice (cases number 307, panels a–d, and 399, panels e–h) and one p53
D2-10 mouse (case number 627, panels i-l).
Immunohistochemical detection of proliferating cell nuclear antigen (PCNA) shows that all three tumors were highly proliferative (panels c, g, and k).
Immunohistochemical staining for p53 (Panels d, h, and l) showing that none of the tumors express p53 protein, consistent with the conditional
inactivation of the LoxP-flanked p53 allele. B) Immunohistochemical staining of Brca1
D5-13;p53
D2-10 case number 307, a representative tumor, shows
that the tumor is highly proliferative (PCNA staining, panel a), but does not express other common differentiation markers. Immunostaining for a-
inhibin (panel b) shows isolated positively staining follicular cells and little or no staining of the tumor cells. Similarly, immunohistochemical detection
of markers of lymphoid (CD45, panel c) epithelial (cytokeratins 8 and 19, panels d and e respectively) and stromal (a-smooth muscle actin, panel f)
differentiation are not detected in tumor cells. Scale bars in each image represent 100 mm.
doi:10.1371/journal.pone.0008404.g003
Brca1 and p53 Ovarian Tumors
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Although the lifetime risk of developing ovarian cancer is
increased in women with germline mutations of BRCA1,
previous studies in mice suggest that loss of Brca1 alone was
insufficient to lead to the development of EOC [22,23,25]. A
number of independent studies [11,12,13,14] have shown that
in cases of EOC with BRCA1 mutations, the frequency of
mutations of p53 is high, ranging from 70–90%. Moreover, in
mouse models of mammary cancer, tumor latency is decreased
and incidence of tumor formation increased in mice with both
conditional inactivation of Brca1 and a p53 null allele [15]. This
apparent cooperation of Brca1 and p53 in inherited breast and
ovarian cancer in humans and in mammary tumor development
in mice led us to create a mouse model of ovarian cancer by
conditional inactivation of Brca1 and p53 in the ovarian
epithelium.
Mice that are null or heterozygous for p53 are highly prone to
developing tumors, particularly lymphomas and sarcomas [33,34].
For reasons that are not completely understood, the occurrence of
epithelial tumors is relatively rare. More recent studies [27,35]
show that mice that have homozygous or heterozygous missense
mutations of p53 develop tumors with similar latency and
spectrum to that of mice that are p53 null or heterozygous, but
that they also develop osteosarcomas and carcinomas with higher
frequency. Missense mutations of p53 have been shown to confer
gain-of-function phenotypes compared to p53 null mutations
[27,35]. Therefore, to develop a mouse model of Brca1- and p53-
associated inherited EOC, we used two approaches for inactiva-
tion or mutation of p53. First, we predicted that using a strategy for
Figure 4. Brca1
D5-13;p53
D2-10 tumors exhibit a high degree of genomic instability. A) Array based comparative genomic hybridization was
performed using genomic DNA isolated from p53
D2-10 (case #627) and Brca1
D5-13;p53
D2-10 (cases #307 and #399) ovarian tumors and shows that
while p53
D2-10 tumors exhibit alterations consistent with aneuploidy, the Brca1
D5-13;p53
D2-10 ovarian tumors exhibit complex patterns of
chromosomal copy number changes, with gains and losses apparent within the same chromosome. B) The high degree of genetic instability was
verified by metaphase chromosome analysis of a cell line derived from Brca1
D5-13;p53
D2-10 tumor #399.
doi:10.1371/journal.pone.0008404.g004
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LoxP/LoxP in combi-
nation with Brca1
LoxP/LoxP in the OSE would result in predispo-
sition for the development of ovarian carcinomas. The second
approach was based on the idea that missense mutations of p53
confer gain-of-function phenotypes and possibly alter tissue
specificity, favoring the development of carcinomas [27,35].
Therefore, we also employed a mouse model expressing a
missense mutation of p53 (p53
515A, analogous to the p53 R175H
hotspot mutation in human cancers [27]) in conjunction with
Brca1
LoxP/LoxP. Our results were consistent with previous findings in
that ovary-specific conditional inactivation of either Brca1 or p53
alone rarely resulted in the development of invasive tumors
[19,22,23,25]. However, Cre-mediated conditional inactivation of
both Brca1 and p53 resulted in the development of tumors in 56%
(23/41) of the mice evaluated. Although mice heterozygous for the
p53
+/515A mutant allele develop tumors (i.e., lymphomas or
sarcomas) with similar latency to p53
+/2 mice [27], we
hypothesized that in mice that had also undergone Cre-mediated
conditional inactivation of Brca1, ovarian carcinoma development
might either out-pace or occur coincidentally with tumors at other
sites. However, in spite of additional ovary-specific conditional
inactivation of Brca1, tumors necessitating euthanasia developed at
sites other than the ovary in Brca1
LoxP/LoxP;p53
+/515A and Brca1
LoxP/LoxP;
p53
LoxP/515A mice. Histopathological evaluation revealed no ovarian
or reproductive tract tumors in these mice. The strain of mice used
in our study had been previously crossed with mice expressing
Cre-recombinase under transcriptional control of the CMV gene
promoter resulting in constitutive expression of the p53
515A allele.
It is therefore unknown whether mice would develop ovarian
tumors if expression of p53
+/515A or p53
LoxP/515A were confined only
to the OSE. Our results do suggest that ovarian tumor develop-
ment in Brca1
LoxP/LoxP;p53
+/515A and Brca1
LoxP/LoxP;p53
LoxP/515A
mice would require long latency and/or additional genetic alterations.
BRCA1-associated ovarian carcinomas in women typically
exhibit serous histology [1]. Histopathological evaluation of the
22 Brca1
D5-13;p53
D2-10 and two p53
D2-10 reproductive tract tumors
unexpectedly showed a complex spectrum of tumors; ovarian
leiomyosarcomas and sarcomas were most prevalent. In women,
primary ovarian sarcomas are exceptionally rare [36], with very
little known regarding the molecular alterations that contribute to
their development. The reason for the lack of ovarian adenocar-
cinoma development in Brca1
LoxP/LoxP;p53
LoxP/LoxP mice given
intrabursal injections of Ad5-CMV-Cre is unclear. Given the
demonstration of highly selective ovarian surface epithelium
infection after intrabursal administration of adenovirus, it seems
unlikely to be due to technical issues associated with the injection
procedure. The long latency between Ad5-CMV-Cre administra-
tion and the detection of tumors (,4006100 days) and the high
degree of genomic instability detected in tumors by aCGH and
karyotyping analysis strongly suggests that additional events are
required for ovarian tumorigenesis. This is consistent with
previous findings [25] showing that ex vivo conditional inactivation
of both Brca1 and p53 in ovarian explants was insufficient for
transformation, whereas the addition of Myc cooperated to induce
transformation in these cells. One possible explanation for the high
incidence of ovarian leiomyosarcomas is that ovarian stromal cells
may be coincidentally infected after intrabursal injection of Ad5-
CMV-Cre and that the combined loss of both Brca1 and p53
renders this population of cells more susceptible to transformation
than the ovarian surface epithelium. Consistent with this is the
observation that p53 null mice frequently develop sarcomas
[33,34]. Cre-mediated recombination of p53
LoxP/LoxP alleles results
in deletion of p53 exons two through ten, thus rendering the cells
and tissues undergoing recombination effectively p53 null.
Although this may potentially explain the high frequency of
ovarian leiomyosarcomas observed, a previous study employing
intrabursal adenovirus-Cre-recombinase mediated inactivation of
LoxP-flanked sequences in p53
LoxP/LoxP;Rb
LoxP/LoxP mice report-
ed a high prevalence of ovarian carcinomas rather than
leiomyosarcomas [19], suggesting the explanation may be more
complicated than just relative tissue susceptibility in mice with p53
mutations.
An alternative explanation for the lack of epithelial cancers in
this model comes from several recent studies [37,38,39,40]
suggesting the precursor lesion of ovarian tumors arising in
BRCA1 mutation carriers may reside in the fallopian tube rather
than the ovarian surface epithelium. These studies have nominat-
ed regions of distal fallopian tube mucosa exhibiting stabilized p53
protein, termed ‘‘p53 signatures’’, and occult non-invasive
intraepithelial serous carcinomas identified in prophylactic
salpingo-oophorectomy specimens of BRCA1 mutation carriers as
candidate precursors of invasive ovarian and/or pelvic serous
carcinomas. In fact, some suggest ‘‘p53 signatures’’ present in
distal fallopian tube of non-BRCA1 carriers as a plausible site of
tumor origin for many sporadic ovarian and peritoneal cancers
[41]. This may suggest that in attempting to model inherited
EOC, the relevant target tissue for recombination and excision of
Brca1 and p53 may not be the OSE, but rather the epithelium of
the distal fallopian tube. Based on the anatomy of murine distal
fallopian tube and ovary, intrabursal injection of Ad5-CMV-Cre
would be predicted to result in viral contact with at least a portion
of the tubal fimbria. This prediction is supported by our
observation of isolated b-galactosidase positive cells present in
the fallopian tube after intrabursal injection of Ad5-CMV-LacZ.
However, this strategy appears to result in less frequent
recombination in the fallopian tube than the OSE. Interestingly,
in a very recent study that used a genetic approach for
reproductive tract restricted Cre-recombinase expression by
crossing Amhr2-Cre transgenic mice with Brca1
LoxP/LoxP and/or
p53
LoxP/LoxP mice showed that while Cre-mediated recombination
of floxed Brca1 and p53 alleles could be demonstrated in the
ovaries, fallopian tubes and uteri of compound transgenic mice,
the tumors that developed in these mice were all uterine
leiomyosarcomas rather than ovarian tumors of any type [42].
Further studies will likely elucidate whether secretory epithelial
cells of the tubal fimbria are the primary cell of origin of BRCA1-
associated and/or sporadic serous ovarian carcinomas. If this is the
case, an alternate strategy for development of mouse models of
inherited Brca1-associated, and possibly sporadic serous EOC,
would be to develop a transgenic strain of mice that express the
Cre-recombinase gene under transcriptional control of a gene
expressed selectively in the fallopian tube epithelium, such as the
oviduct-specific glycoprotein 1 gene [43,44].
Unlike other tumor suppressor genes, loss or mutation of
BRCA1 confers a selective risk for cancer development in organs
such as breast, ovary and prostate. The mechanisms of enhanced
tissue-specific risk are unclear, but suggest that production of or
responsiveness to hormones may play an important role. Recent
work suggests that BRCA1 inactivation contributes to ovarian
tumor development by cell non-autonomous mechanisms [22]. In
this study, investigators used a Cre/LoxP strategy to specifically
inactivate Brca1 in the granulosa cells of the mouse ovary by
crossing Brca1
LoxP/LoxP mice to transgenic mice expressing Cre-
recombinase under transcriptional control of the follicle stimulat-
ing hormone receptor (Fshr) gene promoter. Otherwise genetically
normal female mice with Brca1 inactivated only in granulosa cells
developed benign epithelial ovarian neoplasms [22]. Analysis of
microdissected epithelial lesions confirmed that no excision of the
Brca1 and p53 Ovarian Tumors
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restricted conditional inactivation of Brca1 in granulosa cells is
sufficient to induce neoplastic alterations in the epithelial
compartment in a cell non-autonomous manner. Recent evidence
suggests an additional role for BRCA1 in the regulation of
aromatase P450 (CYP19), the enzyme that catalyzes conversion of
androgen to estrogen [45]. Results from this study suggest that
BRCA1 mutation and loss of heterozygosity may predispose cancer
formation in steroidogenic tissues by virtue of loss of DNA damage
repair mechanisms in the epithelial cell compartments coupled
with growth stimulatory paracrine effects on these cells mediated
by enhanced estrogen production in local tissues (i.e., granulosa
cells and/or preadipocytes). Other studies suggest that selective
inactivation of BRCA1 or p53 in the stroma surrounding tumors
plays a direct role in tumor progression in steroidogenic organs
[46,47,48]. Interestingly, recent work showed that cells exhibiting
a senescence associated secretory phenotype (SASP) contribute to
epithelial to mesenchymal transitions and invasiveness in a cell
non-autonomous manner, with inactivation of p53 being a major
contributor to these pro-malignant paracrine activities [49]. It is
well-established that genetic and/or epigenetic alterations within
the underlying tumor stroma have a direct effect on tumor
progression (reviewed in [50]). Hence, it is clear that stromal-
epithelial interactions are critical to both normal ovarian tissue
function and to epithelial tumor initiation and progression in this
hormone responsive organ.
Taken together, previously published studies and our own data
suggest that loss of function of BRCA1 and p53 cooperate in their
contribution to ovarian tumorigenesis, but that additional
molecular or epigenetic alterations within tumor cells and/or
stroma as well as cell non-autonomous factors contribute to the
development of EOC. Further analyses are required to elucidate
the mechanisms of BRCA1-mediated transformation of the
ovarian epithelium.
Materials and Methods
Mutant Mouse Strains
All procedures in this study involving mice were approved by
the Fox Chase Cancer Center Institutional Animal Care and Use
Committee (IACUC). Mice harboring LoxP flanked sequences in
Brca1 (FVB;129-Brca1
tm2Brn) [16] and p53 (FVB;129-Trp53
tm1Brn)
[26] were obtained from the Mouse Models of Human Cancer
Consortium (MMHCC) Mouse Repository (http://mouse.ncifcrf.
gov/, National Cancer Institute, Frederick, MD) and maintained
as homozygous colonies expressing the conditional alleles
(Brca1
LoxP/LoxP and p53
LoxP/LoxP). Mice harboring an arginine to
histidine substitution at amino acid 172 of p53 (p53
515A/515A) [27],
a mutation corresponding to the p53 hot spot mutation at Arg 175
in humans [28,29,30], were generously provided by Dr.
Guillermina Lozano, University of Texas MD Anderson Cancer
Center, Houston, TX). Mice harboring conditional (LoxP flanked)
alleles of Brca1 or p53 or mutant p53 (Brca1
LoxP/LoxP, p53
LoxP/LoxP
and/or p53
515A/515A) were intercrossed to generate colonies with
the following compound genotypes: Brca1
LoxP/LoxP;p53
LoxP/LoxP,
Brca1
LoxP/LoxP;p53
+/515A and Brca1
LoxP/LoxP;p53
LoxP/515A.
Preparation of Genomic DNA and Genotyping Analysis
Genomic DNA was isolated from tail biopsies by overnight
digestion in sodium chloride (NaCl)/Tris EDTA/proteinase K
solution at 55uC and ethanol precipitation as previously described
[17]. Mice harboring the Brca1
LoxP/LoxP allele were genotyped as
described [16,23] using primers flanking introns 4 (Brca1-int4-Fwd-
59-TATCACCACTGAATCTCTACCG -39 and Brca1-int4-Rev-
59-GACCTCAAACTCTGAGATCCAC-39) and 13 (Brca1-int13-
Fwd-59-TATTCTTACTTCGTGGCACATC-39 and Brca1-int13-
Rev-59-TCCATAGCATCTCCTTCTAAAC-39). The expected
sizes of wild type and LoxP flanked Brca1 sequences were 390 nt
and 545 nt for intron 4 and 494 nt and 620 nt for intron 13
respectively. Mice harboring the p53
LoxP/LoxP allele were genotyped
as previously described [26] using primers flanking introns 1 (p53-
int1-Fwd-59-CACAAAAACAGGTTAAACCAG-39 and p53-int1-
Rev-59-AGCACATAGGAGGCAGAGAC-39) and 10 (p53-int10-
Fwd-59-AAGGGGTATGAGGGACAAGG-39andp53-int10-Rev-
59-GAAGACAGAAAAGGGGAGGG-39). The expected sizes of
wild type and LoxP flanked p53 sequences were 288 nt and 370 nt
for intron 1 and 431 nt and 584 nt for intron 10 respectively. Mice
harboring mutant p53
515A allele(s) were genotyped as previously
described [51] using primers PL5-59-ACCTGTAGCTCCAG-
CACTGG-39, PL6-59-ACAAGCCGAGTAACGATCAGG-39 and
NeoR-59-CCATTTGTCACGTCCTGCACG-39.
Genomic DNA was isolated from bulk tumor tissue using the
same method as described above. Alternatively, microscopic
tumors were manually microdissected. Briefly, adjacent H&E
stained sections were aligned with unstained paraffin embedded
tissue sections to identify the area containing the tumor lesion
which was then scraped with needles or scalpel blades as
described [52,53]. The microdissected tissue was then depar-
affinized in xylenes and genomic DNA isolated by standard
methods for phenol/chloroform/ethanol extraction [52,53].
Purified genomic DNA was used for PCR amplification and
detection of LoxP-flanked and excised Brca1
LoxP/LoxP, p53
LoxP/LoxP
alleles. Cre recombinase-mediated excision of LoxP flanked
sequences in Brca1
LoxP/LoxP m i c er e s u l t si nd e l e t i o no fe x o n s5 – 1 3
(Brca1
D5-13) and was detected by PCR amplification of genomic
DNA with the Brca1-int4-Fwd and Brca1-int13-Rev primers.
Detection of the 594 nt Brca1
D5-13 PCR product confirmed
excision. Similarly, Cre-mediated excision of LoxP flanked
sequences in p53
LoxP/LoxP mice resulting in deletion of exons 2–
10 (p53
D2-10) was detected by amplification of a 612 nt PCR
product from genomic DNA amplified with the p53-int1-Fwd and
p53-int10-Rev primers.
Adenovirus Administration
Replication defective recombinant adenoviruses expressing LacZ
(Ad5-CMV-ntLacZ) or Cre-recombinase (Ad5-CMV-Cre) were
purchased from the Gene Transfer Vector Core, University of
Iowa, Iowa City, IA. To demonstrate our capability to successfully
perform intrabursal injections, we performed pilot experiments in
which 8 week-old female C57Bl/6 mice received intrabursal
injections of Ad5-CMV-ntLacZ as previously described
[18,19,21,23,54]. To synchronize ovulation, female mice were
injected intraperitoneally (i.p.) with 5 U of pregnant mare serum
gonadotropin, followed 48 hours later by i.p. injection with 5 U of
human chorionic gonadotropin (hormones purchased from Sigma,
St. Louis, MO). In preparation for surgery, mice were anesthetized
by intraperitoneal injection of 95 mL per 10 gram body weight of
10 mg/mL Ketamine hydrochloride solution and 1 mg/mL
Xylazine hydrochloride 36 hours following the last hormone
injection. The ovaries were accessed and exposed through a dorsal
incision and each ovary received a single intrabursal injection of
approximately 10 mL( 5 610
7 plaque forming units, p.f.u.) of Ad5-
CMV-ntLacZ virus by inserting a 32G needle coupled with a
Hamilton syringe through the oviduct near the infundibulum into
the ovarian bursa.
For Cre-mediated excision of LoxP-flanked Brca1
LoxP/LoxP and/
or p53
LoxP/LoxP alleles, mice received intrabursal injections of Ad5-
CMV-Cre-recombinase (5610
7 p.f.u.) as described above for Ad5-
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intrabursal injection of Ad5-CMV-Cre or unilateral injection of
PBS (controls) and monitored daily for wellness for the first ten
days post-surgery. Thereafter, mice were monitored at least twice
a week for wellness and the development of palpable tumors. Once
tumors were detected, mice were monitored daily until euthanasia.
Mice were euthanized by CO2 asphyxiation if estimated tumor
palpable tumor volume reached 10% of the total body weight or if
mice exhibited any signs of loss-of-wellness, as per IACUC
guidelines.
Detection of Ad5-CMV-ntLacZ Infection and
Ad5-CMV-Cre-Mediated Excision
Mice infected with Ad5-CMV-ntLacZ were euthanized 7 days
after intrabursal injection. Ovaries were removed, embedded in
OCT medium (Tissue-Tek), snap frozen in liquid N2 and 10 mm
sections cut with a cryostat. Sections were fixed for 10 minutes in
0.5% glutaraldehyde, followed by two rinses with PBS+0.1%
Tween-20, then stained with X-gal solution (1 mg/mL X-gal
(Promega, Madison, WI), 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6,
1 mM MgCl2 in phosphate-buffered saline (PBS)) at 37uC
overnight in a humidified chamber. Sections were rinsed twice
in PBS+0.1% Tween-20, counterstained with Nuclear Fast Red,
dehydrated with alcohols, cleared in xylenes, and coverslipped
using Permount (Fisher).
Tissue restricted Ad5-CMV-Cre infection and Cre-mediated
excision of LoxP flanked alleles was confirmed by isolation of
genomic DNA from ovary, uterus and liver tissue excised from
mice seven days after intrabursal injection of Ad5-CMV-Cre.
Tissues were digested in NaCl/Tris EDTA/proteinase K solution
at 55uC and genomic DNA isolated as described [17]. A tissue
lysate enriched for digested OSE was prepared by limiting the
initial digestion time of ovary specimens at 55uC to 30 min. After
the first 30 min., the samples were centrifuged briefly at low speed
(1000 rpm) to pellet the undigested ovary. The supernatant was
collected and genomic DNA was immediately isolated. To
continue digestion of the remainder of the ovary, a fresh aliquot
of NaCl/Tris-EDTA/proteinase K digestion buffer was added
and the sample digested overnight along with other tissue
specimens. Genomic DNA was isolated the following day and
subjected to PCR amplification with Brca1 intron 4 and intron 13
primers for detection of LoxP flanked and excised sequences as
described above.
Preparation and Analysis of Tissues, Histology and
Immunohistochemistry
All mice were euthanized by CO2 asphyxiation, necropsied and
examined for gross abnormalities. Pathologically altered organs,
entire reproductive tracts and representative specimens of multiple
organs and tissues, including the brain, lung, liver, kidney, spleen,
pancreas and intestine were removed at necropsy, fixed in 10% (v/
v) neutral buffered formalin (NBF) overnight, transferred to 70%
ethanol and paraffin-embedded. In mice with evident tumor,
specimens of the tumor tissue were also excised, snap frozen in
liquid N2 and stored at 280uC. For histological analysis, 5 mm
formalin fixed paraffin embedded tissue sections were cut for
either H&E staining or immunohistochemistry (IHC). Histopath-
ological analysis was performed by a Board Certified Surgical
Pathologist with expertise in human and murine gynecological
malignancies (LHE).
Sections of tumor tissue for immunohistochemical (IHC)
staining were cut on SuperFrost Plus charged slides (Fisher).
Antigens (dilution and source of primary antibodies indicated in
parenthesis) detected by IHC included: Proliferating nuclear
antigen (PCNA, 1:1000; Biogenex), p53 (1:400; Vector Labs),
cytokeratin 8 and 19 (CK8, 1:100 and CK19, 1:50; Developmen-
tal Studies Hybridoma Bank, The University of Iowa), CD3
(1:100; DAKO), CD45R/B220 (1:200; Pharmingen), a-smooth
muscle actin (a-SMA, 1:100; Sigma) and a-inhibin (1:50; Serotec).
Unstained sections were deparaffinized, subjected to antigen
retrieval and stained as described [17].
Establishment of Ovarian Cancer Cell Lines and Cell
Culture
To establish a cell line from an ovarian tumor, approximately
1c m
3 fragments of tumor were excised under aseptic conditions,
transferred to a 10 cm
2 cell culture dish and finely minced using
sterile scalpel blades. Minced tumor tissue was further disaggre-
gated by passing several times through a syringe coupled with a
21K G needle. The suspension of minced tumor tissue was plated
directly in DMEM supplemented with 4% FBS, 1X insulin/
transferring/selenium (ITS), penicillin/streptomycin (100 units/
mL and 2 mM L-glutamine, and incubated at 37uCi n5 %C O 2.
The culture medium was changed twice weekly until the cells
reach confluence at which time they were trypsinized and
passaged at 4–5 day intervals.
Array CGH and Karyotype Analysis
For aCGH, high quality genomic DNA (0.5 to 3 mg) was
isolated from frozen tumor specimens using standard methods and
digested with restriction endonucleases AluIa n dRsaI according to
the Agilent Oligonucleotide Array-based CGH for Genomic DNA
Analysis Version 4.0 protocol. The digested genomic DNA was
labeled using Agilent Genomic DNA Labeling Kit PLUS. Test
and reference DNA samples were labeled with either cyanine 5- or
cyanine 3-dUTP, according to the manufacturer’s instructions.
Cyanine 5- and cyanine 3-labeled DNA products were then
purified using Microcon YM-30 (Millipore) filtration devices. The
DNA yield and level of dye incorporation were measured using
the ND-1000 Spectrophotometer. Appropriate cyanine 5- and
cyanine 3-labeled DNA sample pairs were combined and then
mixed with mouse Cot-1 DNA, Agilent 10X Blocking Agent, and
Agilent 2X Hybridization Buffer. The labeled target solution was
hybridized to Agilent 244K Mouse Genome CGH microarray
(G4415A) using SureHyb chambers. After hybridization the
microarrays were washed and dried according to the procedures
described in the manufacturer’s protocol. Microarray slides were
scanned immediately using an Agilent microarray scanner. Data
for individual features on the microarray were extracted from the
scan image using Agilent Feature Extraction (FE) Software.
Output files from FE were imported into Agilent CGH data
analysis software, CGH Analytics for DNA copy number
analysis.
A tumor cell line established from a Brca1
D5-13;p53
D2-10 ovarian
leiomyosarcoma was subjected to karyotype analysis. Preparation of
metaphase spreads and trypsin-Giemsa (G) banding were per-
formed according to standard procedures. Chromosome identifica-
tion and karyotypes designations were in accordance with the
University of Washington guidelines (http://www.pathology.
washington.edu/research/cytopages/idiograms/mouse/).
Statistical Analysis
The Kaplan-Meier method was used to construct survival plots
for each data set. Comparisons of each of the data sets were made
using the Log-Rank test.
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